3/5 Neurocognitive and neuroimaging biomarkers: predicting progression towards dementia in patients with treatment resistant late-life depression
3/5 Neurocognitive and neuroimaging biomarkers: predicting progression towards dementia in patients with treatment resistant late-life depression
批准号:
9420061
负责人:
MERYL A BUTTERS
金额:
$45.24万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-18 至 2022-07-31
关键词:
AddressAgeAgingAlzheimer&aposs DiseaseAmericanAntidepressive AgentsBiological MarkersBrainBrain imagingCaringChronicClinicalClinical TrialsCognitiveDataDementiaDisease remissionEducationElderlyEnrollmentEpisodic memoryFamilyFundingGenderGoalsImageImpaired cognitionImpairmentIncidenceIndividualInflammatoryInterventionLeadLinkLong-Term CareMagnetic Resonance ImagingMajor Depressive DisorderMedicalMemory LossMental DepressionModelingMolecularMolecular ProfilingNeurocognitiveNeurocognitive DeficitOutcomeParticipantPathway interactionsPatient-Focused OutcomesPatientsPeripheralPharmacotherapyPhenotypePlasma ProteinsPopulationPositioning AttributePrevalencePreventive careProteinsPublic HealthRandomizedRecruitment ActivityResearch InfrastructureResearch InstituteResistanceRiskRisk FactorsSample SizeSiteSuicideTestingTherapeuticTimeVascular DementiaWorkbasecognitive functioncognitive performancecortico-limbic circuitscostdepressive symptomsdesigneffective therapyexecutive functionexperiencegeriatric depressionhigh riskhigh risk populationimprovedindexinginnovationlearning strategymolecular markerneural circuitneuroimagingneuroimaging markernovelolder patientpersistent symptompredictive markerpredictive toolspreventrelating to nervous systemsenescencetreatment response
中文摘要
项目摘要
描述:痴呆症,尤其是阿尔茨海默氏痴呆症(AD),是一个日益严重的公共卫生问题,
仅在美国的患病率为5 M(全球为33 M)。尽管发病率有所下降,但随着年龄的增长,
在美国,痴呆症的患病率预计将增加到1600万(全球1.15亿),
相关成本上升至1 T美元。将美国老年人的长期护理延迟1个月将节省600亿美元
每年的直接护理费用。预防或延迟痴呆症的努力在很大程度上是不成功的。然而,在这方面,
老年抑郁症(“晚年抑郁症”,LLD)已被确定为六种可治疗的风险之一
痴呆症,特别是AD和血管性痴呆的因素。抑郁与痴呆的关系可能是
在对抗抑郁药物治疗无反应并出现持续症状的老年人中,这种情况会被放大。
因此,解决那些患有难治性晚年抑郁症(TRLLD)的人是否有更高的风险,
与治疗反应性LLD患者相比,
重要.
利用以患者为中心的结局研究所(PCARI)资助的治疗研究,N=1500
在5个地点的LLD患者中,我们建议全面描述神经认知和神经成像
与患有持续性LLD的人进展为痴呆相关的生物标志物(即,TRLLD)相比,
那些LLD通过治疗缓解的人。我们预计将招募750名患有LLD的长者,
24个月的症状轨迹。我们将在三个时间点评估每位参与者的神经认知功能,
和先进的神经成像技术我们假设,执行功能和执行控制的变化
网络,以及情景记忆和默认模式/皮质边缘网络的变化,将在
与TRLLD相比,那些对治疗有反应并保持良好的人。我们还假设,
两年的执行功能和情景记忆将与执行功能的变化特别相关,
控制和皮质边缘电路。
根据我们最近的发现,炎症和相关分子标记物可以区分那些与
神经认知功能障碍和LLD从那些与LLD单独,我们将建立一个预测多变量模型
结合基线神经认知,神经影像学和血浆蛋白数据,以确定谁是最大的风险,
认知能力下降和痴呆。最后,我们还将探讨抑郁症患者的潜在阶级轨迹是否
症状可以超越缓解/不缓解的二分法,以确定LLD的老年人亚群,
认知能力下降、神经回路改变和进展为痴呆症的风险最高。
这项工作将为神经回路靶向预防性护理奠定基础,以延缓老年患者亚群的痴呆症
与LLD如果成功,我们的工作可以加速针对抑郁症的治疗努力和创新-
痴呆症的途径,并减少大量老年人及其家人的痛苦。
英文摘要
PROJECT SUMMARY
DESCRIPTION: Dementia, especially Alzheimer's dementia (AD), is a growing public health problem with a
prevalence of 5M in the US alone (33M worldwide). Despite a decrease in incidence rates, with the aging of
the population, the prevalence of dementia is expected to increase to 16M in the US (115M worldwide) with
associated costs rising to $1T. Delaying long-term care by 1 month for older Americans would save $60B
annually in direct care cost. Efforts to prevent or delay dementia have been largely unsuccessful. However,
major depressive disorder in late life (“late-life depression”, LLD) has been identified as one of six treatable risk
factors for dementia, especially AD and vascular dementia. The depression-dementia relationship may be
magnified in elders who do not respond to antidepressant treatment and experience persistent symptoms.
Thus, resolving whether those with treatment-resistant late-life depression (TRLLD) are at higher risk of
cognitive decline and progression to dementia compared to those with treatment-responsive LLD is critically
important.
Leveraging a Patient-Centered Outcomes Research Institute (PCORI)-funded treatment study of N=1500
people with LLD, across 5 sites, we propose to comprehensively delineate neurocognitive and neuroimaging
biomarkers associated with progression to dementia in people with persistent LLD (i.e., TRLLD) compared to
those whose LLD remits with treatment. We anticipate enrolling 750 elders with LLD and characterizing their
symptomatic trajectory over 24 months. We will assess each participant at three time points with neurocognitive
and advanced neuroimaging. We hypothesize that changes in executive functions and the executive control
network, as well as changes in episodic memory and the default mode/cortico-limbic network, will be greater in
those with TRLLD than in those who respond to treatment and stay well. We also hypothesize that changes over
two years in executive function and episodic memory will be specifically associated with changes in executive-
control and cortico-limbic circuitry, respectively.
Based on our recent findings that inflammatory and related molecular markers can differentiate those with
neurocognitive impairment and LLD from those with LLD alone, we will build a predictive multivariate model
combining baseline neurocognitive, neuroimaging, and plasma protein data to determine who is at greatest risk for
cognitive decline and dementia. Finally, we will also explore whether latent class trajectories of depressive
symptoms can go beyond the dichotomy of remission/non-remission to identify subsets of elders with LLD at
highest risk of cognitive decline, neural circuit change, and progression to dementia.
This work will set the stage for neural circuit- targeted preventive care to delay dementia in subsets of older patients
with LLD. If successful, our work can accelerate therapeutic efforts and innovation targeting the depression-
dementia pathway and reduce suffering for large numbers of elders and their families.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Major Depression and Molecular Senescence: The Role of Sleep
-
批准号:10493092
-
项目类别:
-
资助金额:$10.98万
-
财政年份:2021
-
负责人:MERYL A BUTTERS
-
依托单位:
3/5 Neurocognitive and neuroimaging biomarkers: predicting progression towards dementia in patients with treatment resistant late-life depression
-
批准号:9755505
-
项目类别:
-
资助金额:$49.83万
-
财政年份:2017
-
负责人:MERYL A BUTTERS
-
依托单位:
3/5 Neurocognitive and neuroimaging biomarkers: predicting progression towards dementia in patients with treatment resistant late-life depression
-
批准号:9981019
-
项目类别:
-
资助金额:$43.18万
-
财政年份:2017
-
负责人:MERYL A BUTTERS
-
依托单位:
3/5 Neurocognitive and neuroimaging biomarkers: predicting progression towards dementia in patients with treatment resistant late-life depression
-
批准号:10223153
-
项目类别:
-
资助金额:$40.59万
-
财政年份:2017
-
负责人:MERYL A BUTTERS
-
依托单位:
Amyloid, white matter hyperintensities & outcomes of late-life depression
-
批准号:8235036
-
项目类别:
-
资助金额:$49.59万
-
财政年份:2009
-
负责人:MERYL A BUTTERS
-
依托单位:
Amyloid, white matter hyperintensities & outcomes of late-life depression
-
批准号:8488366
-
项目类别:
-
资助金额:$17.05万
-
财政年份:2009
-
负责人:MERYL A BUTTERS
-
依托单位:
Amyloid, white matter hyperintensities & outcomes of late-life depression
-
批准号:7649755
-
项目类别:
-
资助金额:$46.14万
-
财政年份:2009
-
负责人:MERYL A BUTTERS
-
依托单位:
Amyloid, White Matter Hyperintensities & Outcomes of Late-Life Depression
-
批准号:8882920
-
项目类别:
-
资助金额:$6.53万
-
财政年份:2009
-
负责人:MERYL A BUTTERS
-
依托单位:
Pathways Linking Late-Life Depression to MCI & Dementia
-
批准号:7896344
-
项目类别:
-
资助金额:$33.18万
-
财政年份:2009
-
负责人:MERYL A BUTTERS
-
依托单位:
Amyloid, white matter hyperintensities & outcomes of late-life depression
-
批准号:8049633
-
项目类别:
-
资助金额:$49.75万
-
财政年份:2009
-
负责人:MERYL A BUTTERS
-
依托单位:
Amyloid, white matter hyperintensities & outcomes of late-life depression
-
批准号:8417720
-
项目类别:
-
资助金额:$35.77万
-
财政年份:2009
-
负责人:MERYL A BUTTERS
-
依托单位:
Amyloid, white matter hyperintensities & outcomes of late-life depression
-
批准号:7804613
-
项目类别:
-
资助金额:$50.77万
-
财政年份:2009
-
负责人:MERYL A BUTTERS
-
依托单位:
Pathways Linking Late-Life Depression to MCI & Dementia
-
批准号:7107880
-
项目类别:
-
资助金额:$35.12万
-
财政年份:2005
-
负责人:MERYL A BUTTERS
-
依托单位:
Pathways Linking Late-Life Depression to MCI & Dementia
-
批准号:7261397
-
项目类别:
-
资助金额:$32.61万
-
财政年份:2005
-
负责人:MERYL A BUTTERS
-
依托单位:
Pathways Linking Late-Life Depression to MCI & Dementia
-
批准号:7485702
-
项目类别:
-
资助金额:$32.29万
-
财政年份:2005
-
负责人:MERYL A BUTTERS
-
依托单位:
Pathways Linking Late-Life Depression to MCI & Dementia
-
批准号:6979922
-
项目类别:
-
资助金额:$35.56万
-
财政年份:2005
-
负责人:MERYL A BUTTERS
-
依托单位:
Pathways Linking Late-Life Depression to MCI & Dementia
-
批准号:7668406
-
项目类别:
-
资助金额:$33.44万
-
财政年份:2005
-
负责人:MERYL A BUTTERS
-
依托单位:
Pharmacotherapy of Latelife Generalized Anxiety Disorder
-
批准号:7343166
-
项目类别:
-
资助金额:$16.05万
-
财政年份:2005
-
负责人:MERYL A BUTTERS
-
依托单位:
Pharmacotherapy of Latelife Generalized Anxiety Disorder
-
批准号:7161371
-
项目类别:
-
资助金额:$25.98万
-
财政年份:2005
-
负责人:MERYL A BUTTERS
-
依托单位:
COURSE OF COGNITIVE FUNCTIONING IN LATE LIFE DEPRESSION
-
批准号:6736336
-
项目类别:
-
资助金额:$11.65万
-
财政年份:2000
-
负责人:MERYL A BUTTERS
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: